Loading company
Ligand Pharmaceuticals Inc.
LGND · Nasdaq · ·
Next earnings: November 5, 2026
$310.37-1.2%Sep 29 close
- 1M
- +10.7%
- 6M
- +61.1%
- 1Y
- +75.2%
- 5Y
- +120.9%
LGND · Nasdaq · ·
Next earnings: November 5, 2026
$310.37-1.2%Sep 29 close
Ligand Pharmaceuticals Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $63.7M | $47.6M | +33.73% |
| Profit | $48.5M | $4.8M | +900.78% |
| Profit per share | $2.22 | $0.24 | +825.00% |
| Free Cash Flow | $24M | $15.6M | +53.94% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Ligand delivered another strong quarter, with royalty revenue growing 32% year-over-year and continued momentum from Filspari following its FSGS approval by the FDA,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 200 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Ligand Pharmaceuticals Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Ligand Pharmaceuticals Inc. has no earnings call transcript available.